布地奈德联合氨溴索治疗慢性阻塞性肺疾病急性加重期疗效观察

目的探讨布地奈德混悬液联合氨溴索雾化吸入治疗慢性阻塞性肺疾病（COPD）急性加重期患者的临床疗效。方法选择急性加重期的COPD患者160例，按入院先后顺序分为观察组与对照组，每组各80例。对照组给予持续低流量吸氧、抗感染、平喘、止咳化痰及维持水电解质酸碱平衡等常规治疗。观察组在常规治疗的基础上，给予布地奈德混悬液联合氨溴索雾化吸入。观察比较两组各项临床疗效指标。结果观察组总有效率为95．O％，对照组总有效率为81．25％，两组比较差异有统计学意义（P〈0．05）。两组患者组内治疗前、后的血气情况比较差异均有统计学意义（P〈0．05），治疗后两组血气情况比较差异无统计学意义（P〉0．05）。观察组无明显不良反应发生。结论布地奈德联合氨溴索雾化吸入治疗COPD急性加重期疗效好，无明显不良反应，值得临床推广使用。

Clinical efficacy of Budesonide combined with ambroxol in treatment of chronic obstructive pulmonary disease with acute exacerbation

Objective To explore the clinical efficacy of aerosol inhalation of budesonide uspension combined with ambroxol in treatment of chronic obstructive pulmonary disease patients with acute exacerbation. Methods According to the order of admission, 160 patients with acute exacerbation of COPD were divided into observation group and control group, each group was 80 cases. Control group was given continuous low flow oxygen, antibiotics, asthma and cough and phlegm and main- taining water and electrolyte acid - base balance and other conventional treatment. On the basis of conventional therapy, the observation group was given aerosol inhalation of budesonide uspension combined with ambroxol. The clinical indicators are ob- served and compared. Results The total efficiency of observation group was 95.0% and the control group was 81.25% ,the difference was significant between the groups（ P 〈 0.05 ）. The blood of patients before and after treatment were significantly different within the group （ P 〈 0. 05 ） and no significant difference between the two groups （ P 〉 0.05 ）. Observed group has no adverse reactions. Conclusion Aerosol inhalation of budesonide combined with ambroxol in treatment of acute exacerbation of COPI） has good efficacy, no adverse reactions, is worthy of clinical use.